2024-10-07 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Overview:**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer goods company.

* **Cumulative Return:** 33.77%
* **S&P 500 (VOO) Cumulative Return:** 133.14%
* **Performance Gap:** -99.37% 
* **Relative Performance:** 5.34% (This indicates that JNJ's performance is currently positioned at the 5.34th percentile of its historical performance range compared to the S&P 500.)

**2. Recent Price Movements:**

* **Closing Price:** $160.29
* **5-Day Moving Average:** $161.20
* **20-Day Moving Average:** $163.72
* **60-Day Moving Average:** $161.09

**3. Technical Indicators:**

* **RSI:** 19.93 (This suggests that the stock is oversold and could be poised for a rebound, although a continued decline is possible.)
* **PPO:** -0.38 (A negative PPO reading indicates a downtrend, and a value below -20 is considered bearish.)
* **Delta_Previous_Relative_Divergence:** -13.51 (Negative value indicates a short-term downtrend.)
* **Expected Return:** 0.0% (This represents the maximum potential 5-year return compared to the S&P 500, taking into account the current investment amount.)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | $22.45B |
| 2024-05-01 | 1.35 | $21.38B |
| 2024-02-16 | 1.68 | $21.39B |
| 2023-10-27 | 10.32 | $21.35B |
| 2024-02-16 | 10.32 | $21.35B |

The most recent earnings report (2024-07-25) showed that JNJ beat analysts' expectations, with EPS of $1.95 against an estimated $1.87. Revenue came in at $22.45B, slightly exceeding the forecast of $22.38B. This positive earnings report could potentially support a rebound in the stock price.

**5. News and Recent Developments:**

* **Recent Market Outlook:** JNJ has faced some headwinds recently, including litigation surrounding its talcum powder products and declining sales in its pharmaceutical segment. However, the company has a strong portfolio of consumer healthcare brands and continues to invest in research and development. 
* **Analyst Opinions:** Many analysts remain optimistic about JNJ's long-term prospects, citing its strong brand portfolio, diversified business model, and attractive dividend yield.
* **Performance Highlights:** JNJ has a long history of consistent dividend payouts, making it a popular choice for income-oriented investors. 

**6. Overall Analysis:**

JNJ's current performance is lagging behind the broader market, as evidenced by its significantly lower cumulative return compared to the S&P 500. Technical indicators suggest that the stock is oversold, and recent positive earnings could provide some support for a price rebound. 

However, the company faces challenges from lawsuits and declining pharmaceutical sales. Despite these challenges, JNJ has a strong brand portfolio, a diversified business model, and a history of consistent dividend payouts.  

**7. Recommendations:**

Investors seeking a stable, dividend-paying stock with a long history of performance could consider adding JNJ to their portfolio. However, it is important to monitor the company's progress in resolving its legal issues and the performance of its pharmaceutical segment.  

**Disclaimer:** This report is for informational purposes only and should not be considered investment advice.  Always conduct your own research and consult with a financial advisor before making any investment decisions. 
